Objective: tumor angiogenesis can be refined into steps including vascular endothelial matrix degradation, endothelial cell migration, and endothelial cell proliferation, endothelial cell pipeline branch formation of ...Objective: tumor angiogenesis can be refined into steps including vascular endothelial matrix degradation, endothelial cell migration, and endothelial cell proliferation, endothelial cell pipeline branch formation of a vascular ring and a new basement membrane formation. In the process, some imperfect vascular matrix or abnormal new vascular structure and function will occur, which will directly lead to microvascular leakage. Based on this situation, we found that the tumor cells can penetrate directly into the blood vessels, circumvent the complex invasion process, and form the metastasis of the cancer cells at the distant sites. The targeted drug therapy of this disease is an anti-tumor angiogenic targeted drug. With the promotion of drugs, anti-tumor angiogenic targeted drugs bring more and more cardiovascular adverse reaction events. How to eliminate or improve the cardiovascular adverse reactions in patients during the use of anti-tumor angiogenic targeted drugs has become an important clinical problem, and has received more and more attention. To effectively control the frequency of their adverse reactions, an effective analysis of cardiovascular adverse reactions for anti-tumor angiogenesis-targeted drugs is needed.展开更多
文摘Objective: tumor angiogenesis can be refined into steps including vascular endothelial matrix degradation, endothelial cell migration, and endothelial cell proliferation, endothelial cell pipeline branch formation of a vascular ring and a new basement membrane formation. In the process, some imperfect vascular matrix or abnormal new vascular structure and function will occur, which will directly lead to microvascular leakage. Based on this situation, we found that the tumor cells can penetrate directly into the blood vessels, circumvent the complex invasion process, and form the metastasis of the cancer cells at the distant sites. The targeted drug therapy of this disease is an anti-tumor angiogenic targeted drug. With the promotion of drugs, anti-tumor angiogenic targeted drugs bring more and more cardiovascular adverse reaction events. How to eliminate or improve the cardiovascular adverse reactions in patients during the use of anti-tumor angiogenic targeted drugs has become an important clinical problem, and has received more and more attention. To effectively control the frequency of their adverse reactions, an effective analysis of cardiovascular adverse reactions for anti-tumor angiogenesis-targeted drugs is needed.
